1111637-94-5

Basic information

• Product Name: 5-Bromo-3-methyl-7-azaindole
• Synonyms: 5-Bromo-3-methyl-7-azaindole;5-Bromo-3-methyl-1H-pyrrolo[2,3-b]pyridine;5-BroMo-3-Methyl-7-azaind...;1H-Pyrrolo[2,3-b]pyridine, 5-broMo-3-Methyl-;5-bromo-3-methyl-pyrrolo[2,3-b]pyridine
• CAS NO: 1111637-94-5
• Molecular Formula: C₈H₇BrN₂
• Molecular Weight: 211.05858
• Mol File: 1111637-94-5.mol

Chemical Properties

• Appearance: /
• Density: 1.654±0.06 g/cm3(Predicted)
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 13.22±0.40(Predicted)
• CAS DataBase Reference: 5-Bromo-3-methyl-7-azaindole(CAS DataBase Reference)
• NIST Chemistry Reference: 5-Bromo-3-methyl-7-azaindole(1111637-94-5)
• EPA Substance Registry System: 5-Bromo-3-methyl-7-azaindole(1111637-94-5)

Safety Data

• Hazardous Substances Data: 1111637-94-5(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
5-Bromo-3-methyl-7-azaindole is used as a building block for the preparation of various biologically active molecules and pharmaceuticals. Its unique structure allows for the development of new drugs with potential therapeutic applications.
Used in Organic Synthesis:
5-Bromo-3-methyl-7-azaindole is used as a precursor in the synthesis of other heterocyclic compounds. Its reactivity and functional groups make it a valuable component in the creation of complex organic molecules.
Used in Anticancer Research:
5-Bromo-3-methyl-7-azaindole has been studied for its potential anticancer properties. Its ability to interact with biological targets and modulate cellular pathways makes it a promising candidate for the development of new cancer therapies.
Used in Anti-inflammatory Research:
5-Bromo-3-methyl-7-azaindole has also been investigated for its potential anti-inflammatory properties. Its capacity to modulate inflammatory responses and reduce inflammation-related symptoms could lead to the development of new treatments for inflammatory diseases.
Used as a Research Tool in Organic Chemistry:
5-Bromo-3-methyl-7-azaindole serves as a valuable research tool in the field of organic chemistry. Its unique structure and reactivity make it an ideal candidate for studying reaction mechanisms, exploring new synthetic routes, and developing innovative chemical methodologies.

Upstream product

• 1111637-93-4 5-bromo-3-methyl-2-(trimethylsilyl)-1H-pyrrolo[2,3-b]pyridine 
• 875639-15-9 5-bromo-3-iodo-1-(4-methylbenzene-1-sulfonyl)-1H-pyrrolo[2,3-b]pyridine 
• 1207626-51-4 5-bromo-1-tosyl-1H-pyrrolo[2,3-b]pyridine-3-carbaldehyde 
• 1620574-93-7 (5-bromo-1-tosyl-1H-pyrrolo[2,3-b]pyridin-3-yl)methanol 
• 1620574-94-8 5-bromo-3-(chloromethyl)-1-tosyl-1H-pyrrolo[2,3-b]pyridine 
• 1620574-95-9 5-bromo-3-methyl-1-tosyl-1H-pyrrolo[2,3-b]pyridine 
• 757978-18-0 3-iodo-5-bromo-1H-pyrrolo[2,3-b]-pyridine 
• 77992-44-0 5-bromo-2-hydrazinylpyridine 
• 98545-74-5 allyl-(3,5-dibromo-pyridin-2-yl)-amine 
• 35486-42-1 2-amino-3,5-dibromopyridine 

Downstream Products

• 1111637-95-6 3-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrrolo[2,3-b]pyridine 
• 1111637-97-8 5-bromo-3-methyl-1-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridine 
• 916258-24-7 tert-butyl 5-bromo-3-methyl-1H-pyrazolo[3,4-b]pyridine-1-carboxylate 

Relevant articles and documents

2'-(QUINOLIN-3-YL)-5',6'-DIHYDROSPIRO[AZETIDINE-3,4'-PYRROLO[1,2-B]PYRAZOLE]-1-CARBOXYLATE DERIVATIVES AND RELATED COMPOUNDS AS MAP4K1 (HPK1) INHIBITORS FOR THE TREATMENT OF CANCER

The present invention relates to Map4K1 inhibitors of formula (I), to pharmaceutical compositions and combinations comprising the compounds according to the invention, and to the prophylactic and therapeutic use of the inventive compounds, respectively to the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular for neoplastic disorders, respectively cancer or conditions with dysregulated immune responses or other disorders associated with aberrant MAP4K1 signaling, as a sole agent or in combination with other active ingredients. The present invention further relates to the use, respectively to the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of protein inhibitors in benign hyperplasias, atherosclerotic disorders, sepsis, autoimmune disorders, vascular disorders, viral infections, in neurodegenerative disorders, in inflammatory disorders, in atherosclerotic disorders and in male fertility control.

NOVEL COMPOUNDS AND THEIR USES AS THYROID HORMONE RECEPTOR AGONISTS

A compound of formula (I) or (Ia), or a tautomer or a pharmaceutically acceptable salt thereof is provided. Compounds of formula (II) to (V), or a tautomer or a pharmaceutically acceptable salt thereof are also provided. These compounds and the pharmaceutical compositions containing them are useful for the treatment of diseases such as obesity, hyperlipidemia, hypercholesterolemia and diabetes and other related disorders and diseases, and may be useful for other diseases such as NASH, atherosclerosis, cardiovascular diseases, hypothyroidism, thyroid cancer and other disorders and diseases related thereto． (I), (Ia)

TRICYCLIC DLK INHIBITORS AND USES THEREOF

The invention relates to compounds of formula (I) and salts thereof, wherein ring A and R1-R2 have any of the values defined in the specification. The compounds and salts are useful for treating DLK mediated disorders. The invention also provides pharmaceutical compositions comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, as well as methods of using said compounds, salts, or compositions as DLK inhibitors and for treating neurodegeneration diseases and disorders.

3-SUBSTITUTED PYRAZOLES AND USE AS DLK INHIBITORS

The present invention provides for compounds of Formula (I) and various embodiments thereof, and compositions comprising compounds of Formula (I) and various embodiments thereof. (I) In compounds of Formula I, the groups R1, R2, R3, R4, R5, R6 and R7 have the meaning as described herein. The present invention also provides for methods of using compounds of Formula I and compositions comprising compounds of Formula (I) as DLK inhibitors and for treating neurodegeneration diseases and disorders.

PYRAZOLE COMPOUNDS

The present invention is directed to compounds of Formula (I) and to pharmaceutically acceptable salts thereof, their synthesis, and their use as Raf inhibitors.